Selective AMPA receptor positive allosteric modulator (IC50
values are 0.15, 0.21, 1.66 and 5.65 μ
M for GluA2i
respectively. Potentiates glutamate and AMPA-evoked currents in pre frontal cortex (PFC) pyramidal neurons in vitro
. Has no effect on NMDA- or kainate-evoked currents; also has no effect on K+
ion channels. Potentiates PFC glutamatergic synaptic transmission in vitro
and in vivo
. Induces neurite growth in combination with (S)-AMPA
(Cat. No. 0254) in SH-SY5Y human neuroblastoma cells in vitro
. Also reduces MPTP-induced toxicity in mice. Brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.
O'Neill et al.
LY404187: a novel positive allosteric modulator of AMPA receptors.
Quirk and Nisenbaum
CNS Drug Rev., 2002;8:255
Molecular mechanisms of neurite growth with AMPA receptor potentiation.
Voss et al.
Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator.
Baumbarger et al.